Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

73.50p
   
  • Change Today:
      3.50p
  • 52 Week High: 140.00p
  • 52 Week Low: 58.00p
  • Currency: UK Pounds
  • Shares Issued: 13.33m
  • Volume: 41,468
  • Market Cap: £9.80m
  • RiskGrade: 267

Feedback gets several major orders for 'TexRAD' technology

By Josh White

Date: Monday 22 Oct 2018

LONDON (ShareCast) - (Sharecast News) - Specialist medical imaging technology company Feedback announced on Monday that its operating company, Feedback Medical, has received "a number" of significant new orders for 'TexRAD', its patented image texture analysis technology, from university hospitals across Europe.
The AIM-traded firm said the orders came from Universitair Ziekenhuis Gent in Belgium; Beaujon Hospital, University Hospital Clichy, Service d'Imagerie médicale in France; ICNAS Producao Unip. Lda (Coimbra) in Portugal; and University of Cagliari - Department of Diagnostic Imaging and Radiology in Italy.

It said the collection of orders represented the first for TexRAD in Belgium and Portugal.

The initial areas of research ranged from Crohn's disease, aneurysms and carotid imaging, to liver cancer on routinely-acquired standard computed tomography (CT) and magnetic resonance (MR) images.

Feedback said the research projects would run alongside other projects in the area of oncology, which was the main focus area for the company.

The orders arose from an increase in business development activities during the year, the board explained, including scientific presentations and peer group referrals from previous purchasers of TexRAD.

TexRAD was now used across Europe, with the company saying it was looking to expand its existing customer bases in the US and Asia.

As it outlined in the recent trading update, it had initiated plans for regulatory approval of TexRAD with the US FDA, including 510k as medical device and CFR Chapter 21 part 11 compliance for use in clinical trials of drug candidates for FDA marketing approval.

"These recent orders of TexRAD are further validation of Feedback Medical and our technology," said Feedback Medical's global business development director Dr Balaji Ganeshan.

"We are taking advantage of our growing reputation to drive new business."

Dr Ganeshan said the new business wins had resulted from having referrals from current customers, and penetrating new country markets.

"TexRAD is now being used in a diverse range of research fields which demonstrates the significant potential and applicability of our technology."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 73.50p
Change Today 3.50p
% Change 5.00 %
52 Week High 140.00p
52 Week Low 58.00p
Volume 41,468
Shares Issued 13.33m
Market Cap £9.80m
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
11.64% below the market average11.64% below the market average11.64% below the market average11.64% below the market average11.64% below the market average
37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average
Price Trend
61.44% below the market average61.44% below the market average61.44% below the market average61.44% below the market average61.44% below the market average
11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average
Income Not Available
Growth
52.14% above the market average52.14% above the market average52.14% above the market average52.14% above the market average52.14% above the market average
72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for 17-May-2024

Time Volume / Share Price
14:47 4,900 @ 73.75p
14:46 4,900 @ 72.28p
14:30 350 @ 71.88p
13:49 7,163 @ 69.80p
12:48 38 @ 70.00p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page